Key statistics
As of last trade, Transcode Therapeutics Inc (RNAZ:NAQ) traded at 0.3847, 78.10% above the 52 week low of 0.216 set on Aug 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.3907 |
---|---|
High | 0.3907 |
Low | 0.36 |
Bid | 0.376 |
Offer | 0.3847 |
Previous close | 0.38 |
Average volume | 408.05k |
---|---|
Shares outstanding | 17.27m |
Free float | 17.26m |
P/E (TTM) | -- |
Market cap | 6.56m USD |
EPS (TTM) | -8.49 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 17:12 GMT.
More ▼
- TransCode Therapeutics Open Letter to Shareholders
- TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
- TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
- TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
- TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
- TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
- TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
- TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
- TransCode Therapeutics, Inc. Announces Closing of Public Offering
- TransCode Therapeutics, Inc. Announces Pricing of Public Offering
More ▼